Posłuchajcie interesującego wykładu Prof. Maciej Banach na temat miejsca pitawastatyny w leczeniu zaburzeń lipidowych. Serdecznie zapraszamy oraz zachęcamy do zadawania pytań oraz udziału w dyskusji! 👉 Online: kongres2021.ptlipid.pl/transmisja/ #KongresPTL

Właśnie rozpoczynamy sesję specjalną #KongresPTL, poświęconą laureatom tegorocznej edycji konkursu dla Najwybitniejszych Młodych Lipidologów. 🏆 Serdecznie wszystkich zapraszamy! 👉 Online: kongres2021.ptlipid.pl/transmisja/ #KongresPTL

Gratulacje dla pani Dr Joanny Lewek nagrody dla Najwybitniejszych Młodych Lipidologów #KongresPTL Online: kongres2021.ptlipid.pl/transmisja/ Polskie Towarzystwo Lipidologiczne

Pacjent z niewydolnością serca i zaburzeniami lipidowymi. Najczęściej popełniane błędy – wykład Pani Prof. Agaty Bieleckiej-Dąbrowy na #KongresPTL Online: kongres2021.ptlipid.pl/transmisja/ Polskie Towarzystwo Lipidologiczne

#Ewinakumab - #gamechanger w leczeniu pacjentow z homozygotyczna #FH , a w perspektywie znacznie szerszej grupy pacjentow? Czekamy ba ten lek w Polsce, oby jak najszybciej‼️💪 Dr Bożena Sosnowska z ⁦UMED Lodz (Uniwersytet Medyczny w Łodzi)⁩ ⁦Polskie Towarzystwo Lipidologiczne⁩ #PTL2022

Amazing work by my amazing young associates - Dr Bożena Sosnowska & Stanisław Surma on #LPA. We need to #educate, we need to #measure Lp(a) & re-stratify the risk, we need to be 100% ready before dedicated #drugs will be available. #pelacarsen @olpasiran mdpi.com/1424-8247/15/1…

Today I have also made a #ChristmasGift for myself with 3 #papers published. 1st one on the #evinacumab, an #ANGPTL3 #Inhibitor, in the #Treatment of #Dyslipidemia with my young associates - Stanisław Surma Bożena Sosnowska and Prof. Robert Rosenson. mdpi.com/2077-0383/12/1…

Kurs EAS Advanced Course in rare lipid disorders umed.pl/kurs-eas-advan…

To continue the thread of new Polish #LPA #recommendations - please also see some practical approach to the elevated #LPA levels management 💪 I would especially put your attention on Table 7 with the recommendations on how to manage with the elevated concentration of #LPA in

Whether there is a risk of #HeartFailure with elevated #LPA? See our next results from the #PMMHRI-Lp(a)-#Registry! We showed that despite lack of significantly higher levels of Lp(a) in the HF group, in the multivariable analysis using logistic regression with a backward

Dwie wspaniałe Kobiety, niezwykłe badaczki nt. miażdżycy otrzymują nagrody Polskie Towarzystwo Lipidologiczne Women in Lipid Disorders and Atherosclerosis Award 2024‼️👏👏 Ogromne Gratulacje 🔥 Bożena Sosnowska Anna Bednarek

See the most cited 2024 #AMS paper: "Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels" #LPA #recommendations Congratulations to all Authors! 👏

Our joint recommendations of Polskie Towarzystwo Kardiologiczne and Polskie Towarzystwo Lipidologiczne on the #LPA #diagnosis and #management published in the 1/2024 issue of Archives of Medical Science (AMS) as a highly cited paper in the new #ESI report (Jan 2025) by the Clarivate! Congratulations to Dr Bożena Sosnowska from my team and to all

Like every year in the AMS we try to summary the largest #achievements in the area of Atherosclerotic Cardiovascular Diseases #CVD. This time we have had no doubts, year #2024 definitely belonged to lipoprotein(a) #LPA, taking into account the number of #studies published,

How should we manage dyslipidemia in patients with cancer🎗, heart failure💔, or homozygous FH 🧬? Find out in our “Special Populations” session at #ILEP2025 🗓 June 5–6, 2025 📍 Warsaw 🔗 congress.ilep.eu #Lipidology #Cancer #HF #hoFH #CardioX #PTOK #PTL

Presenting and discussing our research results: Growth differentiation factor 15 and absorption loss as new biomarkers of heart failure decompensation💧🩺🫀🫁 #HeartFailureAwareness #heartfailure2025 #asocjacjaniewydnosciserca

Unique people, unique time, unique meeting, unique place, just #ILEP2025. Thanks 🩷 International Lipid Expert Panel (ILEP)

Dyslipidemia is common in cancer 👫—driven by the disease, treatments, and LS changes—and can worsen both CV risk and cancer outcomes. Lipid monitoring should be routine ◀️,↔️, and▶️ therapy. Guideline-based management and close cardio-oncology collaboration are 🗝️ #ILEP2025

‼️The most read paper in 2025: 2024: The Year in #Cardiovascular #Disease - The Year of Lipoprotein(a) #LPA – Research Advances and New Findings. Bożena Sosnowska Alexander C. Razavi Roger Blumenthal Alan Remaley International Lipid Expert Panel (ILEP) archivesofmedicalscience.com/2024-The-Year-…